Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Vertex Pharmaceuticals price target lowered to $450 from $456 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $456 and keeps an Equal Weight rating on the ...
The Motley Fool13d
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...